SecBot SecBot
8-K ·Filed Nov 2, 2026

TEM

Tempus AI, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed14d 17h ago SEC0001193125-26-442619
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The revenue beat and raised guidance confirm strong execution, but the stock's 6.5% normal daily move means the 23% revenue growth and 33% Data & Apps growth are already partly priced in. Watch the Personalis shareholder vote on Nov 30 and Q4 cash flow trends for margin inflection.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$78.48
T+0 close · Nov 2, 2026 · via day close
Latest settled
+7.59%
T+5 · $84.44 · next T+20 in 14d
Vs SPY
+7.52%
α at T+5
Latest observation
−9.89%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $78.48entry
  2. T+1 · 14d ago −0.87%α −1.17% · $77.80
  3. T+5 · 8d ago +7.59%α +7.52% · $84.44
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The company raised full-year 2026 revenue guidance to $1.60-$1.605B (from $1.595-$1.605B), representing ~25% annual growth, and reiterated ~$65M Adjusted EBITDA. Key operational highlights include 32% oncology volume growth, 33% Data & Apps revenue growth, and major collaborations with BMS ($137.5M) and Merck/Moderna. The Personalis acquisition cleared regulatory review with a shareholder vote scheduled for November 30, 2026.

Key Financial Metrics

Revenue
$411.5M
est $409.3M · +0.6% · +23.0% YoY
Guidance
$1.60B-$1.605B
raised
Gross Margin
64.8%

Key Facts

  • Q3 2026 total revenue of $411.5M, up 23% YoY from $334.2M
  • GAAP net loss of $(14.9)M vs $(80.0)M in Q3 2025, improvement of 81%
  • Adjusted EBITDA of $25.6M vs $1.5M in Q3 2025, a 1,633% increase
  • Full-year 2026 revenue guidance raised to $1.60-$1.605B from $1.595-$1.605B
  • Data & Applications revenue grew 33% YoY to $108.1M
  • Oncology volume growth accelerated to 32% YoY
  • MRD volume of ~12,000 tests, up 300% YoY
  • BMS collaboration: up to $137.5M over five years for oncology data and models
  • Merck/Moderna multi-year collaboration for individualized neoantigen therapy (INT)
  • Personalis acquisition cleared regulatory review; shareholder vote set for Nov 30, 2026
  • Cash and marketable securities of $854.4M at quarter end
  • Data licensing bookings >$550M year-to-date

Financial Impact

Revenue beat consensus by ~$2.2M (0.5%), guidance raised modestly, Adjusted EBITDA improved sharply to $25.6M from $1.5M

revenueadjusted_ebitdaguidancecash_position

Segment Breakdown

SegmentRevenueGrowth
Diagnostics$303.5M+20.0%
Data and Applications$108.1M+33.0%

Risk Factors

  • Personalis acquisition integration risk and potential dilution
  • Heavy stock-based compensation ($48.1M in Q3) continues to pressure GAAP profitability
  • Revenue concentration in related-party transactions (Pathos AI, SB Tempus)
  • High cash burn: operating cash flow of $(71.6)M YTD 2026

Market Snapshot

Exchange
Nasdaq
Sector
Services-Computer Programming, Data Processing, Etc.
Analyst Consensus
52% bullish (27 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-442619
Document: tem-20261102.htm0001193125-26-442619
Document: 0001193125-26-442619-index-headers.html0001193125-26-442619
Document: 0001193125-26-442619-index.html0001193125-26-442619
Document: 0001193125-26-442619.txt0001193125-26-442619
8-K Data (Synthetic)0001193125-26-442619

Track record

45 reports on TEM

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +53.09% at T+60 after the Jul 30, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 3/10 Entry $80.54 Now $64.76 −19.59% settles Feb 8
  2. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $76.05 Now $64.76 −14.85% settles Feb 4
  3. Nov 4, 202612d ago Insider Cluster Neutral 3/10 Entry $70.43 Now $64.76 −8.05% settles Feb 3
  4. Nov 2, 202614d ago 144 Neutral 1/10 Entry $77.80 Now $64.76 −16.76% settles Feb 1
  5. Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $78.48 Now $64.76 −17.48% settles Jan 29
  6. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $77.84 Now $64.76 −16.80% settles Jan 27
  7. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
  8. Oct 27, 202620d ago 144 Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
  9. Oct 23, 202624d ago 8-K Bullish 6/10 Entry $67.62 Now $64.76 −4.22% settles Jan 21
  10. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $63.81 Now $64.76 +1.49% settles Jan 20
Showing 10 of 45

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026